Literature DB >> 11119712

Generation and degradation of human endostatin proteins by various proteinases.

M Ferreras1, U Felbor, T Lenhard, B R Olsen, J Delaissé.   

Abstract

The angiogenesis inhibitor endostatin is a fragment of the NC1 domain of collagen XVIII. The generation of endostatin has been investigated only in murine hemangioendothelioma cell cultures and was ascribed to cathepsin L. Distinct endostatin-like fragments were detected in human tissues and serum. To identify proteinases able to generate such fragments, we incubated human NC1 with proteinases of all classes, including cathepsin L. Eleven out of 12 generate fragments with an N-terminus within the same 15 residue stretch as those occurring physiologically, indicating that this region is sensitive to many proteinases. None correspond to mouse endostatin. However, the efficiencies of these proteinases differed markedly. Some proteinases also proved to degrade endostatin, pointing to another regulatory loop of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11119712     DOI: 10.1016/s0014-5793(00)02249-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  91 in total

1.  Endostatin regulates branching morphogenesis of renal epithelial cells and ureteric bud.

Authors:  A Karihaloo; S A Karumanchi; J Barasch; V Jha; C H Nickel; J Yang; S Grisaru; K T Bush; S Nigam; N D Rosenblum; V P Sukhatme; L G Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

Review 2.  New functional roles for non-collagenous domains of basement membrane collagens.

Authors:  Nathalie Ortega; Zena Werb
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

3.  Defective p53 antiangiogenic signaling in glioblastoma.

Authors:  Benjamin Berger; David Capper; Dieter Lemke; Philipp-Niclas Pfenning; Michael Platten; Michael Weller; Andreas von Deimling; Wolfgang Wick; Markus Weiler
Journal:  Neuro Oncol       Date:  2010-05-26       Impact factor: 12.300

4.  Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.

Authors:  Olcay Tatar; Kei Shinoda; Annemarie Adam; Tillmann Eckert; Claus Eckardt; Klaus Lucke; Christoph Deuter; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

5.  ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2.

Authors:  Nathan V Lee; Makoto Sato; Douglas S Annis; Joseph A Loo; Lily Wu; Deane F Mosher; M Luisa Iruela-Arispe
Journal:  EMBO J       Date:  2006-11-02       Impact factor: 11.598

6.  Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas.

Authors:  Anna Gruszka; Jolanta Kunert-Radek; Marek Pawlikowski; Henryk Stepien
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 7.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

8.  Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Tillmann Eckert; Gábor B Scharioth; Micheal Klein; Efdal Yoeruek; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

9.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 10.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.